VACCINE FOR CTL IMMUNITY TO HUMAN IMMUNODEFICIENCY VIRUS

这个项目的目标是将方法论发展到最好 细胞毒性T淋巴细胞(CTL)对人类免疫缺陷病毒和 使用非活疫苗的其他病原体。目前，最佳方法做到了 并不是用来启动这种对病毒的关键免疫形式的。这个 开发针对这些病原体的有效疫苗将是非常重要的。 对人和动物都有好处。目前正在采取两种新的方法。 第一种方法将通过利用多肽来激活CTL 与I类主要组织相容性相关的多肽的观察 β2-微球蛋白重新结合时的复杂(MHC)分子。 将开发引入多肽和 β2-微球蛋白在体内形成I类多肽 MHC分子复合物和质数CTL。第二种方法将质数 CTL具有完整的蛋白质通过利用观察到的天然 抗原可以通过一种特殊的抗原递呈方式呈递给CTL。 细胞驻留在正常组织中。我们将开发合适的方法来 促进抗原进入这一抗原呈递途径。这些 将开发与小鼠相关的疫苗方法，以及 然后是人类第一类MHC分子。

The goal of this project is to develop methodology to prime cytotoxic T lymphocyte (CTL) immunity to Human Immunodeficiency Virus and other pathogens using nonliving vaccines. Currently, optimal methods do not exist to prime this critical form of immunity to viruses. The development of efficacious vaccines to these pathogens would be of great benefit to both man and animals. Two novel approaches are being taken. The first approach will prime CTL's with peptides by exploiting the observation that peptides associate with class I Major Histocompatibility Complex (MHC) molecules upon reassociation of beta2-microglobulin. Methods will be developed for introducing peptides and beta2-microglobulin in-vivo in a manner that will form peptide-class I MHC molecule complexes and prime CTL's. The second approach will prime CTL's with intact proteins by exploiting the observation that native antigens can be presented to CTL's by a specialized antigen-presenting cell resident in normal tissues. We will develop suitable methods for enhancing antigen entry into this pathway of antigen-presentation. These approaches will be developed for vaccines in association with murine, and then human class I MHC molecules.